[
  {
    "ts": null,
    "headline": "Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock",
    "summary": "The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday.",
    "url": "https://finnhub.io/api/news?id=a6d538f800498a68bf7629a63d2ab6eec1c8fd7231a9e240c823f311f7a2e495",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734736567,
      "headline": "Vertex Wins An Early Approval; Why It Might Not Move Vertex's Beleaguered Stock",
      "id": 132084060,
      "image": "https://media.zenfs.com/en/ibd.com/df5c1a56168deebdebe2aceaa3ac053c",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "The Food and Drug Administration signed off on Vertex Pharmaceuticals' next-generation triple drug for cystic fibrosis late Friday.",
      "url": "https://finnhub.io/api/news?id=a6d538f800498a68bf7629a63d2ab6eec1c8fd7231a9e240c823f311f7a2e495"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis",
    "summary": "BOSTON, December 20, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Se",
    "url": "https://finnhub.io/api/news?id=931ce3e47b31a4c4dfd483cb6576ea152afd39ee4a029a455962c6b74b50d6e3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734727560,
      "headline": "Vertex Announces US FDA Approval of ALYFTREK™, a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis",
      "id": 132084061,
      "image": "https://media.zenfs.com/en/business-wire.com/8f983a5f283acdb0d5d561ae2bf5f727",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, December 20, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has approved ALYFTREK (vanzacaftor/tezacaftor/deutivacaftor), a once-daily next-in-class triple combination cystic fibrosis transmembrane conductance regulator (CFTR) modulator for the treatment of cystic fibrosis (CF) in people 6 years and older who have at least one F508del mutation or another mutation in the CFTR gene that is responsive to ALYFTREK. Se",
      "url": "https://finnhub.io/api/news?id=931ce3e47b31a4c4dfd483cb6576ea152afd39ee4a029a455962c6b74b50d6e3"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants",
    "summary": "BOSTON, December 20, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In a",
    "url": "https://finnhub.io/api/news?id=a50107a1907b446af20a4885fa4010096f4c7cc189f613e352145452b6521bc8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734726900,
      "headline": "Vertex Announces U.S. FDA Approval for TRIKAFTA (elexacaftor/tezacaftor/ivacaftor and ivacaftor) to Include Additional Non-F508del TRIKAFTA-Responsive Variants",
      "id": 132084062,
      "image": "https://media.zenfs.com/en/business-wire.com/1d6c5d7e0aecf1598be4064357d8307a",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "BOSTON, December 20, 2024--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved the expanded use of TRIKAFTA® (elexacaftor/tezacaftor/ivacaftor and ivacaftor) for the treatment of people with cystic fibrosis (CF) ages 2 and older who have at least one F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene or a mutation that is responsive to TRIKAFTA based on clinical and/or in vitro data. In a",
      "url": "https://finnhub.io/api/news?id=a50107a1907b446af20a4885fa4010096f4c7cc189f613e352145452b6521bc8"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market",
    "summary": "Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market",
    "url": "https://finnhub.io/api/news?id=e2d9a5eb7c8e96df16572ac570f2f1da653af3f1c1d73808268a08d13d93a194",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734712920,
      "headline": "Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market",
      "id": 132148890,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Pharmaceuticals Inc. stock rises Friday, still underperforms market",
      "url": "https://finnhub.io/api/news?id=e2d9a5eb7c8e96df16572ac570f2f1da653af3f1c1d73808268a08d13d93a194"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek",
    "summary": "By Katherine Hamilton Vertex Pharmaceuticals said the Food and Drug Administration approved a new treatment for cystic fibrosis. The treatment, called alyftrek, is designed to treat cystic...",
    "url": "https://finnhub.io/api/news?id=76e4ff17a5ba435f66bfb9579381332737c67279dace4ed6b1944294eabd6885",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734711920,
      "headline": "Vertex Gains FDA Approval for Cystic Fibrosis Drug Alyftrek",
      "id": 132079754,
      "image": "",
      "related": "VRTX",
      "source": "Finnhub",
      "summary": "By Katherine Hamilton Vertex Pharmaceuticals said the Food and Drug Administration approved a new treatment for cystic fibrosis. The treatment, called alyftrek, is designed to treat cystic...",
      "url": "https://finnhub.io/api/news?id=76e4ff17a5ba435f66bfb9579381332737c67279dace4ed6b1944294eabd6885"
    }
  },
  {
    "ts": null,
    "headline": "VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo",
    "summary": "Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.",
    "url": "https://finnhub.io/api/news?id=71f00e9a21497f7d70f4aa6f9a7b22eb919237ab28e477aed080c471bd62792a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734711180,
      "headline": "VRTX Down as Non-Opioid Drug Shows Similar Pain Reduction as Placebo",
      "id": 132084064,
      "image": "https://media.zenfs.com/en/zacks.com/a1d7049b0977a02a21fd2aa02b46f307",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex announces data from a phase II study evaluating its NaV1.8 pain signal inhibitor, suzetrigine, for treating painful lumbosacral radiculopathy. Shares down.",
      "url": "https://finnhub.io/api/news?id=71f00e9a21497f7d70f4aa6f9a7b22eb919237ab28e477aed080c471bd62792a"
    }
  },
  {
    "ts": null,
    "headline": "Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment",
    "summary": "Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment",
    "url": "https://finnhub.io/api/news?id=3f786a6b0462b7b8cbe2e93e70ac9ce83e28ddfdb49f4b56d0d95e42b9dbc7f3",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734710400,
      "headline": "Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment",
      "id": 132148892,
      "image": "",
      "related": "VRTX",
      "source": "MarketWatch",
      "summary": "Vertex Gets Expanded FDA Approval for Cystic Fibrosis Treatment",
      "url": "https://finnhub.io/api/news?id=3f786a6b0462b7b8cbe2e93e70ac9ce83e28ddfdb49f4b56d0d95e42b9dbc7f3"
    }
  },
  {
    "ts": null,
    "headline": "Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?",
    "summary": "Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.",
    "url": "https://finnhub.io/api/news?id=4256c0fd3307dadb6e0e04005880f6000e548f25473fcf41339213d94f2143f0",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734699615,
      "headline": "Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?",
      "id": 132084065,
      "image": "https://media.zenfs.com/en/ibd.com/36341c7359b2a531328260e35b43cafc",
      "related": "VRTX",
      "source": "Yahoo",
      "summary": "Vertex stock was floundering even before Thursday when the company's non-opioid pain drug underperformed expectations in a midstage study.",
      "url": "https://finnhub.io/api/news?id=4256c0fd3307dadb6e0e04005880f6000e548f25473fcf41339213d94f2143f0"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review",
    "summary": "Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review",
    "url": "https://finnhub.io/api/news?id=7d942acb9b559d2d1c72580d2cfc3eb55df24134a9cd3e7782717958add180b9",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1734697221,
      "headline": "Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review",
      "id": 132148870,
      "image": "",
      "related": "VRTX",
      "source": "DowJones",
      "summary": "Stock Market Tumbles, Treasury Yields Soar On Fed Rate Outlook: Weekly Review",
      "url": "https://finnhub.io/api/news?id=7d942acb9b559d2d1c72580d2cfc3eb55df24134a9cd3e7782717958add180b9"
    }
  }
]